Clinical practice shows improved outcomes in metastatic prostate cancer with genomic testing and PARPi therapy, suggesting ongoing research into biomarkers and resistance.
Clinical practice is converging on early comprehensive genomic testing and prioritization of PARPi-based therapy for HRR-altered, especially BRCA1/2-mutated, prostate cancer. Key research priorities include functional biomarkers beyond gene panels, rational combinations to prevent/overcome resistance, and optimized sequencing across disease states.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: